111 related articles for article (PubMed ID: 35632499)
1. Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron.
Vogt AS; Augusto G; Martina B; Chang X; Nasrallah G; Speiser DE; Vogel M; Bachmann MF; Mohsen MO
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632499
[TBL] [Abstract][Full Text] [Related]
2. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
3. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
4. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents.
Ma C; Chen X; Mei F; Xiong Q; Liu Q; Dong L; Liu C; Zou W; Zhan F; Hu B; Liu Y; Liu F; Zhou L; Xu J; Jiang Y; Xu K; Cai K; Chen Y; Yan H; Lan K
Emerg Microbes Infect; 2022 Dec; 11(1):567-572. PubMed ID: 35060426
[TBL] [Abstract][Full Text] [Related]
5. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
6. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
[TBL] [Abstract][Full Text] [Related]
7. The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
Hastert FD; Hein S; von Rhein C; Benz NI; Husria Y; Oberle D; Maier TJ; Hildt E; Schnierle BS
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632550
[TBL] [Abstract][Full Text] [Related]
8. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.
Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Hussaini L; Ciric CR; Nguyen PV; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Sexton M; Piantadosi A; Waggoner JJ; Douek DC; Anderson EJ; Rouphael N; Wrammert J; Suthar MS
bioRxiv; 2021 Dec; ():. PubMed ID: 34981056
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients.
Fu J; Shen X; Anderson M; Stec M; Petratos T; Cloherty G; Montefiori DC; Landay A; Moy JN
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423000
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai W; Huo J; Zhou D; Zahradník J; Supasa P; Liu C; Duyvesteyn HME; Ginn HM; Mentzer AJ; Tuekprakhon A; Nutalai R; Wang B; Dijokaite A; Khan S; Avinoam O; Bahar M; Skelly D; Adele S; Johnson SA; Amini A; Ritter TG; Mason C; Dold C; Pan D; Assadi S; Bellass A; Omo-Dare N; Koeckerling D; Flaxman A; Jenkin D; Aley PK; Voysey M; Costa Clemens SA; Naveca FG; Nascimento V; Nascimento F; Fernandes da Costa C; Resende PC; Pauvolid-Correa A; Siqueira MM; Baillie V; Serafin N; Kwatra G; Da Silva K; Madhi SA; Nunes MC; Malik T; Openshaw PJM; Baillie JK; Semple MG; Townsend AR; Huang KA; Tan TK; Carroll MW; Klenerman P; Barnes E; Dunachie SJ; Constantinides B; Webster H; Crook D; Pollard AJ; Lambe T; ; ; Paterson NG; Williams MA; Hall DR; Fry EE; Mongkolsapaya J; Ren J; Schreiber G; Stuart DI; Screaton GR
Cell; 2022 Feb; 185(3):467-484.e15. PubMed ID: 35081335
[TBL] [Abstract][Full Text] [Related]
11. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant.
Zhou Z; Du P; Li N; Xiong X; Tang S; Dai Q; Wang T; Yu M; Man M; Lam K; Baptista-Hon DT; Tai WH; Monteiro O; Ng WS; Lee UM; Liu Z; Zhang K; Li G
MedComm (2020); 2022 Jun; 3(2):e143. PubMed ID: 35592756
[TBL] [Abstract][Full Text] [Related]
12. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination.
Hein S; Mhedhbi I; Zahn T; Sabino C; Benz NI; Husria Y; Renelt PM; Braun F; Oberle D; Maier TJ; Hildt C; Hildt E
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632552
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
15. Variability in SARS-Cov-2 IgG Antibody Affinity To Omicron and Delta Variants in Convalescent and Community mRNA Vaccinated Individuals.
Tu MK; Chiang SH; Wong DTW; Strom CM
medRxiv; 2022 Mar; ():. PubMed ID: 35262090
[TBL] [Abstract][Full Text] [Related]
16. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
17. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
Gruell H; Vanshylla K; Tober-Lau P; Hillus D; Schommers P; Lehmann C; Kurth F; Sander LE; Klein F
Nat Med; 2022 Mar; 28(3):477-480. PubMed ID: 35046572
[TBL] [Abstract][Full Text] [Related]
18. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
19. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
20. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8
Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AAR
mBio; 2022 Apr; 13(2):e0361721. PubMed ID: 35229637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]